f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

GEM21S Growth Factor


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Completed
Application Number /
Requirement Number		 P040013 S016/ PAS001
Date Original Protocol Accepted 05/27/2011
Date Current Protocol Accepted 12/06/2011
Study Name GEM21S Growth Factor
Device Name GEM 21S GROWTH FACTOR ENHANCED MATRIX
General Study Protocol Parameters
Study Design Bench/Lab Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Detailed Study Protocol Parameters
Study Objectives Stability testing (bench study)
Study Population GEM21S (Formulated rhPDGF-BB) 0.5 mL in a 1 mL syringe on Long Term Stability at 2¢ªC - 8¢ªC (horizontal) will undergo stability testing.
Sample Size Horizontal testing will be performed on at least one production lot annually, and a sample of three production lots will be tested out to 48 months for informational purposes (the current shelf life for the syringe is 42 months).
Key Study Endpoints pH, bioassay, Chromatographic purity evaluation, Protein concentration by analysis using UV, HPLC purity evaluation, SDS Page purity evaluation, sterility evaluation, and bacterial endotoxin evaluation.
Follow-up Visits and Length of Follow-up The stability study will follow each lot for at least 42 months 2-8¢ªC. The first three production batches will be tested through 48 months at 2-8¢ªC.
Long-term temperature Stability testing will be performed at 3, 6, 9, 12, 18, 24, 42 and 48 months.


GEM21S Growth Factor Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 11/25/2011 11/21/2011 On Time
one year report 05/26/2012 05/21/2012 On Time
18 month report 11/24/2012 11/19/2012 On Time
two year report 05/26/2013 06/05/2013 Overdue/Received
three year report 05/27/2014 05/23/2014 On Time
four year report/final report 05/26/2015 05/22/2015 On Time
Rqst to waive next report 06/22/2015 06/22/2015 On Time


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-